Roswell Park Comprehensive Cancer Center | Strategic Alliance Partners

April 03, 2025

Marco Davila, MD, PhD, discusses how a study of tumor drivers of CAR T-cell therapy resistance in LBCL may promote future biomarker investigations.

April 03, 2025

Roswell Park-led study takes a significant step toward relief without opioid.

March 25, 2025

Roswell Park Comprehensive Cancer Center surgeons will share their expertise during the 2025 annual meeting of the Society of Surgical Oncology.

March 20, 2025

Roswell Park Comprehensive Cancer Center has been recognized as a Center of Excellence for both adult and pediatric cancer treatment by Optum.

March 13, 2025

Roswell Park Comprehensive Cancer Center’s Intensive Care Unit has earned the Beacon Award for Excellence from the AACN.

March 12, 2025

Renier Brentjens, MD, PhD, details 3 reasons it’s challenging to make CAR T-cell therapies applicable for solid tumors and ways to overcome the obstacles.

March 10, 2025

Marco Davila, MD, PhD, discusses research investigating ways to combat immune escape mechanisms in LBCL treated with CD19-directed CAR T-cell therapy.

March 06, 2025

Roswell Park’s Dr Kenan Onel leads large international team that sheds light on pineoblastoma and Wilms tumor.

March 03, 2025

5 WNY organizations received funding to advance cancer prevention, early detection, and patient support from Roswell Park Comprehensive Cancer Center.

February 19, 2025

The GVHD Alliance honored Shernan Holtan, MD, of Roswell Park Comprehensive Cancer Center, as the recipient of the 2025 Lukas D. Wartman Award.

February 17, 2025

CDK2 regulates the cell cycle and may have the potential to drive therapeutic resistance to common breast cancer drugs — including CDK4/6 inhibitors.

February 14, 2025

Janine Joseph, MS, MBA, discusses the effects of resistance training interventions on fatigue and pain levels in patients with multiple myeloma.

February 07, 2025

Matthew Cortese, MD, MPH, discusses an evaluation of immunologic changes with the treatment of venetoclax in patients with chronic lymphocytic leukemia.

January 30, 2025

Marco Davila, MD, PhD, discusses emerging strategies to overcome resistance to CD19-directed CAR T-cell therapy in aggressive large B-cell lymphoma.

January 20, 2025

Francisco J. Hernandez-Ilizaliturri, MD, discusses findings from a study investigating immunologic changes in patients with CLL treated with venetoclax.

January 20, 2025

Marco Davila, MD, PhD, explains the role of intrinsic tumor drivers in CD19 CAR T-cell therapy resistance in aggressive large B-cell lymphoma.

January 20, 2025

Laboratory research led by Anna Bianchi-Smiraglia, PhD, reveals therapeutic target in metabolic enzyme IMPDH2.

January 03, 2025

Data published in Oncogene suggest that the mitochondrial unfolded protein response could be an Achilles’ heel for neuroendocrine prostate cancer.

December 20, 2024

A preclinical study showed gilteritinib can strengthen CAR T-cell therapy in two high-risk pediatric leukemias.

December 16, 2024

Sessions at San Antonio Breast Cancer Symposium address exercise, cannabis, sexual health, plus insights on treatment.